Government’s investment of 1.3 billion to boost API manufacturing in India

A turnaround strategy to reduce India’s dependence on China


Following the news that the Indian Government has approved US$ 1.3 billion (approximately Rs 1000 crore) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API), according to Global data report.

Prashant Khadayate, pharma analyst at GlobalData, offers his view, “The package, which is part of a turnaround strategy to reduce India’s dependence on China, will help boost the capabilities of domestic API manufacturers. The timing of the announcement was crucial as Indian pharma companies are facing potential supply disruptions due to the Covid-19 outbreak. Indian pharma manufacturers depend heavily for their supply of fine chemicals and drug intermediates on China.”

According to him, as part of the strategy, three API manufacturing parks will be set up in different parts of the country to further help in setting up API manufacturing units, and incentive scheme will be implemented for the production of government identified 53 API’s by the manufacturers.

China is a key supplier of both Chemical API and chemical intermediates for the global pharmaceutical industry. The Covid-19 outbreak has the potential to disrupt the global supply chain for chemical APIs and impacted pharmaceutical companies globally. The Indian pharma industry needs to protect itself and prepare to improve its intermediate and API manufacturing capabilities and supplies. This will also cement India’s position as a hub of API supply for the global markets in the future.”

According to GlobalData’s ‘Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition’ report, India has the largest number of dedicated contract manufacturing organizations (CMOs) with small molecule API manufacturing facilities approved by the US FDA or the EMA. With the government’s support, the Indian market will be less affected by changes in the supply chain.

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now


Please enter your comment!
Please enter your name here